PALI

Rating neutralTentativeAI Memo

Palisade Bio

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

UEG Week PALI-2108 presentations • 2026-10-20

Base target: $1 / p=40% prob

Biggest risk

PALI-2108 remains clinically unproven in Phase 2. The encouraging Phase 1 patient cohorts contained only five UC and five fibrostenotic Crohn’s patients, while Q2 2026 R&D expense rose to $7.4 million from $1.7 million a year earlier as development scaled. [#SEC-8K-2026-08-10]

Invalidation

Break below $1 or thesis failure.

What would change my mind?

September FDA clearance for ASCENTRA-CD and Health Canada clearance for ASCENTRA-UC remove two regulatory-start hurdles. The company reported $125.2 million of cash at June 30 and expects resources to fund both planned Phase 2 readouts. [#SEC-8K-2026-08-10] [#PR-2026-09-22] [#PR-2026-09-23]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-02

Base target

p=40%

Bull target

p=25%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ASCENTRA-UC first-patient dosing
ASCENTRA-UC primary efficacy results
ASCENTRA-CD primary efficacy results

BearKey bullets

ASCENTRA-CD’s single-arm design may complicate interpretation of efficacy relative to a controlled study.
[#PR-2026-09-22]
Phase 1 signals from very small patient cohorts may not replicate in controlled Phase 2 testing.

WatchKey bullets

UEG Week PALI-2108 presentations

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=40%)

Target spread vs base: +74% / -52%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=40%)Bear Target: $1 (p=35%)

Commentary

The September 22–28 company announcements improve milestone visibility versus the August filing and supersede the prior baseline’s still-pending Crohn’s IND catalyst, but do not resolve efficacy risk. Available public peers offer clinical context, not reliable valuation comparability; the thesis remains tentative. The packet supplies no measured news, social, options, short-interest, employee, or analyst-revision series; zero-valued fields mean unavailable, not neutral. The $1.43 anchor is below the prior baseline’s $1.45, and the negative deterministic prior supports cautious monitoring.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ASCENTRA-UC first-patient dosing
ASCENTRA-UC primary efficacy results
ASCENTRA-CD primary efficacy results

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=40% prob

Bear Target (Scenario probability)

$1 / p=35% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-20
UEG Week PALI-2108 presentations
Palisade plans four presentations on October 18–20 covering previously observed Phase 1b clinical and translational findings. New detail could affect confidence, but these presentations are not a Phase 2 efficacy readout. [#PR-2026-09-28] Source: https://www.globenewswire.com/news-release/2026/09/28/3369880/0/en/palisade-bio-to-present-clinical-and-translational-data-for-pali-2108-in-ulcerative-colitis-and-crohn-s-disease-at-ueg-week-2026.html
Prob 90.00% • Move 5.00% • Priced-in 70.00%
EVENT2027-03-31
ASCENTRA-CD first-patient dosing
The company announced FDA clearance of the Crohn’s disease IND on September 22, superseding August guidance that submission was still pending. It targets first dosing in its approximately 60-patient, single-arm Phase 2 study in Q1 2027. [#SEC-8K-2026-08-10] [#PR-2026-09-22] Sources: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-ex99_1.htm and https://www.globenewswire.com/de/news-release/2026/09/22/3366355/0/en/palisade-bio-receives-fda-clearance-of-ind-for-pali-2108-in-crohn-s-disease-expanding-phase-2-development-across-ibd.html
Prob 65.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

ASCENTRA-UC first-patient dosing
2026-12-31
After U.S. IND and Canadian clinical-trial clearance, Palisade says it remains on track to begin dosing in its approximately 204-patient Phase 2 ulcerative-colitis trial in the second half of 2026. Dosing would confirm execution, not efficacy; delay would weaken confidence. [#8-K-2026-08-10] [#PR-2026-09-23] Sources: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm and https://www.globenewswire.com/news-release/2026/09/23/3367474/0/en/palisade-bio-expands-global-phase-2b-ascentra-uc-program-with-health-canada-cta-clearance.html
Prob 70% • Move 12% • Priced-in 55%

Long-term Catalysts

Months to a year

ASCENTRA-UC primary efficacy results
2027-12-31
The company expects a second-half 2027 readout from its randomized, placebo-controlled Phase 2 trial. The Week 12 clinical-remission endpoint is the principal test of whether encouraging observations in just five Phase 1 UC patients replicate at scale. [#SEC-8K-2026-08-10] [#PR-2026-09-23] Sources: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-ex99_1.htm and https://www.globenewswire.com/news-release/2026/09/23/3367474/0/en/palisade-bio-expands-global-phase-2b-ascentra-uc-program-with-health-canada-cta-clearance.html
Prob 35% • Move 90% • Priced-in 15%
ASCENTRA-CD primary efficacy results
2028-03-31
Palisade targets a Q1 2028 readout of centrally reviewed Week 12 endoscopic response. The open-label, single-arm design and small prior fibrostenotic Crohn’s cohort warrant caution when interpreting a positive signal. [#PR-2026-09-22] Source: https://www.globenewswire.com/de/news-release/2026/09/22/3366355/0/en/palisade-bio-receives-fda-clearance-of-ind-for-pali-2108-in-crohn-s-disease-expanding-phase-2-development-across-ibd.html
Prob 30% • Move 65% • Priced-in 10%

Risks

ASCENTRA-CD’s single-arm design may complicate interpretation of efficacy relative to a controlled study. [#PR-2026-09-22]
Phase 1 signals from very small patient cohorts may not replicate in controlled Phase 2 testing. [#SEC-8K-2026-08-10]
Rising clinical and manufacturing spending may shorten the stated cash runway or eventually require financing despite June 30 cash of $125.2 million. [#SEC-8K-2026-08-10]
Site activation, enrollment, dosing, or readout delays could erode the value of the announced regulatory clearances. [#PR-2026-09-22] [#PR-2026-09-23]

Peers

Symbol	Summary
SYRE	Indication-and-stage comparator only: Spyre reported Phase 2 ulcerative-colitis induction data, but its antibody programs differ from PALI-2108’s oral PDE4 prodrug. Its pipeline and funding also preclude a direct valuation multiple. Source: https://ir.spyre.com/news-releases/news-release-details/spyre-announces-potential-best-class-spy002-anti-tl1a-part
ABVX	Oral ulcerative-colitis clinical benchmark only: Abivax reported Phase 3 maintenance results for obefazimod. Its different mechanism and much later development stage make it unsuitable as a like-for-like valuation peer. Source: https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

SYRE

Indication-and-stage comparator only: Spyre reported Phase 2 ulcerative-colitis induction data, but its antibody programs differ from PALI-2108’s oral PDE4 prodrug. Its pipeline and funding also preclude a direct valuation multiple. Source: https://ir.spyre.com/news-releases/news-release-details/spyre-announces-potential-best-class-spy002-anti-tl1a-part

ABVX

Oral ulcerative-colitis clinical benchmark only: Abivax reported Phase 3 maintenance results for obefazimod. Its different mechanism and much later development stage make it unsuitable as a like-for-like valuation peer. Source: https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial